BioAmicus Complete for Functional Gastrointestinal Symptoms in Infants Aged 0 to 24 Months

Recruiting now · Not applicable

Conditions studied: Infantile Colic, Gastroesophageal Reflux (GER), Functional Constipation, Functional Diarrhea, Dysbiosis

In brief

Infants often experience functional gastrointestinal symptoms (e.g., colic, excessive gas, regurgitation, constipation, or loose stools) that distress families and may reflect an imbalance of the gut microbiome. This study evaluates whether the multistrain probiotic BioAmicus Complete can improve caregiver-reported gastrointestinal symptoms in infants 0-24 months and is safe for use in this population. The primary assessment is the change in the Infant Gastrointestinal Symptom Questionnaire (IGSQ) total score from the start to the end of the study period. Secondary assessments include symptom domains (colic/regurgitation, stool frequency and consistency), caregiver quality of life, growth parameters (weight and length), health care utilization and antibiotic exposure, and overall safety/tolerability (adverse events and serious adverse events). Stool samples will be analyzed to explore changes in the gut microbiome.

Key facts

Study ID

NCT07148583

Run by

Haiphong University of Medicine and Pharmacy

People needed

110

Starts

2025-09-05

Expected to finish

2026-05-30

Last updated by the study team

2026-01-29

Who can join

Age: any, up to 2. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 0-24 months at enrollment.
• Infant has clinician-assessed functional gastrointestinal symptoms (e.g., colic/irritability, regurgitation, constipation, loose stools), judged suitable for study participation.
• Parent or legal guardian provides written informed consent and agrees to comply with study procedures (questionnaires/diaries and sample collection, if applicable).
• Caregivers agree to avoid other probiotic products during the study period, except as directed by the study team.

You may not qualify if…

• Major congenital gastrointestinal anomalies or known chronic gastrointestinal diseases requiring ongoing prescription therapy (e.g., Hirschsprung disease, inflammatory bowel disease, short-bowel syndrome).
• Clinically unstable condition or severe/critical illness that could interfere with participation or safety in the opinion of the investigator.
• Known or suspected primary or secondary immunodeficiency, or current immunosuppressive therapy.
• History of severe allergy or hypersensitivity to components of the investigational product.
• Recent use of systemic antibiotics within 14 days prior to baseline, or use of probiotic supplements within 14 days prior to baseline (per protocol).
• Participation in another interventional clinical trial within 30 days prior to enrollment or during the study.
• Any condition that, in the investigator's judgment, would make the participant unsuitable for the study or confound outcome assessments.

Where it is running

• Clinical Trial and Bioequivalence Center — Haiphong, Hai Phong, Vietnam (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.